Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sightspire: Port Delivery System With Ranibizumab in nAMD
NCT06847542Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2025
- Primary completion
- Nov 2028
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Roche. Primary endpoint: Best Corrected Visual Acuity at 72 weeks. Started Nov 2025; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06847542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847542.